3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
6
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Interventions
darolutamide
3
Pluvicto
3
Docetaxel
3
testosterone 17 beta-cypionate
2
sipuleucel-T
1
lactitol
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
ebastine
1
cabozantinib
1
cabazitaxel
1
Standard of Care
1
Prednisone
1
Prednisolone
1
PSMA-617
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-resistant Prostate Cancer
×
cabazitaxel
×
Clear all
NCT05762536
2024-06-27
DAROTAXEL
Erasmus Medical Center
Phase 2
Recruiting
245 enrolled